Abstract
Background and aims Bempedoic acid significantly lowers low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia but its effects in patients with metabolic syndrome (MetS) have not been well characterized. We sought to determine the efficacy and safety of bempedoic acid in patients with hypercholesterolemia by baseline MetS status.
Methods This study used pooled data from four phase 3 studies. Using modified International Atherosclerosis Society guidelines, patients were grouped into two pools: those with and those without MetS. Patients with diabetes were excluded. Endpoints assessed change from baseline to week 12 in lipid and glycemic parameters and high-sensitivity C-reactive protein (hsCRP), and safety.
Results The study included 936 patients with MetS (bempedoic acid, 648; placebo, 288) and 1573 without MetS (bempedoic acid, 1037; placebo, 536). Significant placebo-corrected reductions in LDL-C were observed with bempedoic acid (p<0.0001), with a greater decrease in patients with vs. without MetS (−22.3% vs. −18.4%; interaction p=0.0472). Compared with placebo, bempedoic acid significantly (p<0.0001) lowered total cholesterol, non–high-density lipoprotein cholesterol, apolipoprotein B, and hsCRP, with a similar magnitude of benefit observed between MetS categories. Significant reductions in triglycerides (−4.4%; p=0.02) were only observed in patients without MetS; only patients with MetS experienced decreases in glycated hemoglobin (−0.07%; p<0.0001) and fasting plasma glucose (−2.4 mg/dL; p=0.002). Safety was comparable between MetS categories and treatment groups.
Conclusions These data suggest that bempedoic acid is a suitable therapy for patients with MetS who require additional lipid lowering.
Highlights
Bempedoic acid lowered LDL-C vs. placebo in patients with and without MetS.
Placebo-corrected LDL-C reductions were greater in patients with vs. without MetS.
Bempedoic acid lowered TC, non–HDL-C, ApoB, and hsCRP regardless of MetS category.
Reductions in HbA1c and FPG vs. placebo were only observed in patients with MetS.
Bempedoic acid safety was comparable between MetS categories.
Competing Interest Statement
Michael D. Shapiro has received research grant(s)/support paid to his institution from Amgen, Esperion, Ionis, the National Institutes of Health, NewAmsterdam Pharma, and Novartis, and honoraria for consultancy from Emendo Bio, Ionis, Novartis, and Regeneron. He has also served on scientific advisory boards for Amgen, Novartis, and Precision BioSciences Pam R. Taub has received funding/grant support from the American Heart Association, the National Institutes of Health, and the Federal Emergency Management Agency, and honoraria for consultancy from Amgen, Bayer, Boehringer Ingelheim, Esperion, Medtronic, Novartis, Novo Nordisk, and Sanofi Michael J. Louie is an employee of Esperion Therapeutics, Inc. Lei Lei is a consultant for Esperion Therapeutics, Inc. Christie M. Ballantyne has received research grant(s)/support paid to his institution from Abbott Diagnostics, Akcea, Amarin, Amgen, Esperion, Ionis, Novartis, Regeneron, Roche Diagnostic, Sanofi Synthelabo, NIH, AHA, and ADA; he has also served as a consultant for Abbott Diagnostics, Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Esperion, Intercept, Ionis, Matinas BioPharma, Inc., Merck, Novartis, Novo Nordisk, Regeneron, Roche Diagnostic, and Sanofi Synthelabo
Funding Statement
This study was sponsored by Esperion Therapeutics, Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All studies were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines, and their respective protocols received approval from local independent ethics committees at each study site.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.